Fenofibrate has been studied in 51 papers since 2002: 9 trials and 7 observational studies in people, 17 in animals, 2 in cells, 15 reviews; 23 in the past year. It is an approved medicine. The newest story, Oct 2, 2026: “Fenofibrate improves cognition in chronic brain injury trial”.
Fenofibrate reduces senescence in human cells and inflammation in mice, with independent replication of both changes. One group reports human results, including a trial showing lower mortality when added to simvastatin in diabetes with hyperlipidemia diagnosed by age 60, but no clear mortality effect with later diagnosis. Some papers declare company ties.
71 findings in 27 papers from 2002 to 2026, 4 of them since May 2026
The findings reach people, from one lab or study; independent labs found the same change in cells and mice. 25 independent labs in 9 countries; 96 trials, 13 about aging, 35 with no results posted.
“Fenofibrate did not reduce AF risk overall, but its effect differed by ACR category with reduced AF risk when ACR <30 mg/g (HR 0.53; 95% CI, 0.27–1.02)”
Cells and mice: replicated by independent labs. Worms or flies and humans: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
25 independent labs in 9 countries
4 findings against
96 trials, 13 about aging, 35 with no results posted
Funders: National Natural Science Foundation of China and others
“In both in vivo and in vitro models of sepsis-induced acute kidney injury (AKI), fenofibrate has been observed to alleviate senescence and inflammation.”
“In both in vivo and in vitro models of sepsis-induced acute kidney injury (AKI), fenofibrate has been observed to alleviate senescence and inflammation.”
Fenofibrate decreases cellular senescence in human cells (IL-6-induced senescence).
“Fenofibrate (FN), a PPARα agonist used for dyslipidaemias in humans, reduced the number of senescent cells via apoptosis, increased autophagic flux, and protected against cartilage degradation.”
Fenofibrate is linked with lower estimated glomerular filtration rate in humans (persistent hypertriglyceridemia on statin therapy).
“Creatinine-based estimated glomerular filtration rate (eGFR) declined during treatment; cystatin C-based eGFR showed a similar direction in a smaller paired subset (n = 135).”
Humanspersistent hypertriglyceridemia on statin therapycholine salt24 weeks
Fenofibrate showed no clear effect on major adverse cardiovascular events in humans (Diabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo) (Nonsignificant trend: HR 0.86, 95% CI 0.64–1.16).
“with a non-significant trend in the late-diagnosed group (HR = 0.86, 95%CI 0.64–1.16; P for interaction = 0.256)”
Human trialDiabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo
Fenofibrate showed no clear effect on mortality in humans (Diabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo) (HR 1.12, 95% CI 0.81–1.55).
“but not in the late-diagnosed group (HR = 1.12, 95% CI 0.81–1.55; P for interaction = 0.006)”
Human trialDiabetes with hyperlipidemia diagnosed at >60 years; added to simvastatin versus placebo
Fenofibrate showed no clear effect on HbA1c in humans (three-group comparison (placebo, curcumin, fenofibrate) added to glimepiride).
“no significant differences were found regarding weight, body mass index, fasting blood glucose, two-hour postprandial glucose (2 h-PPG), and HbA1c (p > 0.05)”
Human trialthree-group comparison (placebo, curcumin, fenofibrate) added to glimepiride160 mg once dailythree months
Studies link fenofibrate with 7 measures, among them atherosclerotic cardiovascular disease, cardiovascular mortality and major adverse cardiovascular events.
Atherosclerotic cardiovascular disease
↓downin humans1
1 study
Fenofibrate is linked with a lower risk of atherosclerotic cardiovascular disease in humans (statin-treated individuals with TRL-C ≥ median (26 mg/dl)) (HRadj 0.76, 95% CI 0.59-0.99).
“fenofibrate use was associated with lower ASCVD risk in individuals with TRL-C ≥ median (adjusted hazard ratio [HRadj] 0.76; 95% confidence interval [CI] 0.59-0.99)”
Humansstatin-treated individuals with TRL-C ≥ median (26 mg/dl)mean follow-up of 87 months
Fenofibrate lowers the risk of cardiovascular mortality in humans (Diabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo) (HR 0.47, 95% CI 0.30–0.74).
“a significant decrease in death from cardiovascular causes among early-diagnosed hyperlipidemia group (HR 0.47, 95% CI 0.30–0.74; P for interaction = 0.07)”
Human trialDiabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo
Fenofibrate lowers the risk of major adverse cardiovascular events in humans (Diabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo) (HR 0.69, 95% CI 0.55–0.88).
“fenofibrate reduced major adverse cardiovascular events (MACEs) risk in the early-diagnosed group (HR = 0.69, 95%CI 0.55–0.88)”
Human trialDiabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo
Fenofibrate lowers the risk of mortality in humans (Diabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo) (HR 0.57, 95% CI 0.41–0.79).
“Fenofibrate significantly reduced all-cause mortality risk in the early-diagnosed group (HR = 0.57, 95% CI 0.41–0.79)”
Human trialDiabetes with hyperlipidemia diagnosed at ≤60 years; added to simvastatin versus placebo
Fenofibrate is associated with atrial fibrillation in type 2 diabetes with baseline ACR <30 mg/g (HR 0.53; 95% CI, 0.27–1.02).
“Fenofibrate did not reduce AF risk overall, but its effect differed by ACR category with reduced AF risk when ACR <30 mg/g (HR 0.53; 95% CI, 0.27–1.02)”
Human trialin type 2 diabetes with baseline ACR <30 mg/gmedian 4.9 years
A human trial shows that fenofibrate improves cognitive function and decreases NfL in older adults with cTBI. Animal experiments in the same paper show decreased inflammatory monocyte/macrophage infiltration into the brain in cTBI.
Among 31,604 matched pairs, people taking the drugs had a dementia hazard ratio of 0.454 compared with statin users, indicating lower relative risk.Among 31,604 matched pairs, people taking the drugs had a dementia hazard ratio of 0.454 compared with statin users, indicating lower relative risk.